Bristol Myers Squibb Co (BMY) Shareholder Cypress Asset Management Has Trimmed Its Stake; Euclidean Technologies Management Lowered Its Best Buy (BBY) Stake as Stock Value Rose

December 6, 2017 - By Michael Collier

Cypress Asset Management Inc decreased its stake in Bristol Myers Squibb Co (BMY) by 17.43% based on its latest 2017Q2 regulatory filing with the SEC. Cypress Asset Management Inc sold 12,638 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 59,869 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $3.34 million, down from 72,507 at the end of the previous reported quarter. Cypress Asset Management Inc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $100.71 billion market cap company. The stock decreased 0.79% or $0.49 during the last trading session, reaching $61.53. About 1.11M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 6, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Euclidean Technologies Management Llc decreased its stake in Best Buy Inc (BBY) by 25.08% based on its latest 2017Q2 regulatory filing with the SEC. Euclidean Technologies Management Llc sold 11,500 shares as the company’s stock rose 13.46% with the market. The hedge fund held 34,361 shares of the consumer services company at the end of 2017Q2, valued at $1.97M, down from 45,861 at the end of the previous reported quarter. Euclidean Technologies Management Llc who had been investing in Best Buy Inc for a number of months, seems to be less bullish one the $17.91B market cap company. The stock decreased 0.63% or $0.39 during the last trading session, reaching $61.25. About 1.05 million shares traded. Best Buy Co., Inc. (NYSE:BBY) has risen 62.80% since December 6, 2016 and is uptrending. It has outperformed by 46.10% the S&P500.

Cypress Asset Management Inc, which manages about $488.07 million US Long portfolio, upped its stake in At&T Inc (NYSE:T) by 37,967 shares to 113,566 shares, valued at $4.29 million in 2017Q2, according to the filing. It also increased its holding in Du Pont E I De Nemours & Co (NYSE:DD) by 38,952 shares in the quarter, for a total of 84,198 shares, and has risen its stake in Danaher Corp Del (NYSE:DHR).

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 EPS, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 22.96 P/E if the $0.67 EPS becomes a reality. After $0.75 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. As per Wednesday, August 16, the company rating was maintained by Credit Suisse. The rating was maintained by BMO Capital Markets with “Sell” on Monday, November 13. The company was initiated on Wednesday, April 6 by Societe Generale. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Monday, July 17 by Deutsche Bank. BMO Capital Markets maintained the shares of BMY in report on Sunday, July 23 with “Sell” rating. Piper Jaffray maintained the shares of BMY in report on Thursday, July 27 with “Hold” rating. The stock has “Hold” rating by Jefferies on Tuesday, June 14. The firm earned “Hold” rating on Thursday, August 27 by Jefferies. The firm has “Hold” rating by Cowen & Co given on Monday, August 14. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, October 13 with “Equal-Weight” rating.

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It dived, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Smith Chas P Associate Pa Cpas has invested 0.07% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Seizert Cap Partners Ltd Limited Liability Company holds 0.02% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 8,845 shares. Wealthtrust holds 0.06% in Bristol-Myers Squibb Company (NYSE:BMY) or 1,950 shares. Panagora Asset Mngmt holds 0.04% or 193,838 shares in its portfolio. Concert Wealth Management has invested 0.53% in Bristol-Myers Squibb Company (NYSE:BMY). 19,490 are owned by Btim Corp. Jfs Wealth Lc reported 1,305 shares. Bluecrest Cap Management Ltd, a Guernsey-based fund reported 10,931 shares. North Amer owns 11,600 shares. Stonebridge Cap owns 76,340 shares or 1.12% of their US portfolio. Moreover, Tower Research Capital (Trc) has 0.03% invested in Bristol-Myers Squibb Company (NYSE:BMY). Kistler stated it has 0.34% in Bristol-Myers Squibb Company (NYSE:BMY). Rice Hall James & Associates accumulated 0.01% or 4,788 shares. Ar Asset Mgmt invested in 1.36% or 59,924 shares. Texas Yale Cap reported 15,625 shares.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Nasdaq.com which released: “Madrona Financial Services, LLC Buys ONEOK Inc, Boeing Co, Bristol-Myers …” on November 09, 2017, also Investorplace.com with their article: “Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating” published on December 01, 2017, Bloomberg.com published: “Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact” on December 01, 2017. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Investorplace.com and their article: “3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers …” published on December 04, 2017 as well as Investorplace.com‘s news article titled: “Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating” with publication date: November 24, 2017.

Among 27 analysts covering Best Buy Co (NYSE:BBY), 10 have Buy rating, 4 Sell and 13 Hold. Therefore 37% are positive. Best Buy Co had 92 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, May 15 by Loop Capital. The firm has “Neutral” rating by Bank of America given on Thursday, November 17. The firm has “Overweight” rating by Barclays Capital given on Thursday, September 14. The stock of Best Buy Co., Inc. (NYSE:BBY) earned “Buy” rating by Piper Jaffray on Wednesday, September 20. The rating was maintained by Jefferies on Tuesday, July 4 with “Hold”. The firm has “Buy” rating given on Thursday, November 16 by Loop Capital Markets. Deutsche Bank maintained the shares of BBY in report on Wednesday, August 24 with “Hold” rating. RBC Capital Markets maintained it with “Hold” rating and $5400 target in Friday, June 30 report. The firm has “Buy” rating by SunTrust given on Wednesday, August 24. The firm has “Outperform” rating given on Friday, May 26 by Telsey Advisory Group.

More notable recent Best Buy Co., Inc. (NYSE:BBY) news were published by: Investorplace.com which released: “Best Buy Co Inc Has Found Its Niche – And So Has Its Stock” on November 22, 2017, also Investorplace.com with their article: “Best Buy Co Inc Stock Has Finally Made Its Turnaround Move” published on December 01, 2017, Investorplace.com published: “Best Buy Co Inc Stock Is Still Worth Shopping For” on November 28, 2017. More interesting news about Best Buy Co., Inc. (NYSE:BBY) were released by: Usnews.com and their article: “Best Buy Flies High With Holiday Sales” published on November 28, 2017 as well as Nasdaq.com‘s news article titled: “Best Buy Co Inc. Q3 Profit Climbs 23%” with publication date: November 16, 2017.

Since June 9, 2017, it had 0 insider purchases, and 2 selling transactions for $2.31 million activity. Watson Mathew had sold 503 shares worth $29,679.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: